An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Stomach Neoplasms Clinical Trial

Official title:

An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00226811
• Other study ID #: A6181054
• Status: Completed
• Phase: Phase 2
• First received: September 23, 2005
• Last updated: March 10, 2015
• Start date: January 2006
• Est. completion date: May 2008

Study information

• Verified date: March 2015
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study consisted of two parts. In Part 1 the study enrolled 38 patients (Step 1 Simon 2 step design) after which Step 2 was opened and the total enrollment target for the study (n=63) was exceeded due to a rapid enrollment (78 patients were entered). Part 2 of the study did not open due to the final overall insufficiency of efficacy observed in 78 patients. Sunitinib (SU011248) was administered orally daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg with provision for dose reduction based on tolerability. All patients received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria were met. After discontinuation of treatment, patients were followed up in order to collect information on further antineoplastic therapy and survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Gastric or gastroesophageal junction adenocarcinoma cyto/histologically documented

• Disease progression/ recurrence after treatment with one prior single agent or combination chemotherapy regimen for advanced / metastatic disease (last dose at least 4 wks before study entry). Patients may have also received prior adjuvant therapy if recurrence occurred > 6 months after adjuvant therapy completion

• Evidence of measurable disease by radiographic technique

• Adequate organ function.

Exclusion Criteria:

• Clinically relevant ascites (i.e. requiring paracentesis)

• Severe weight loss

• NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment

• Diagnosis of second malignancy within last 3 years

• History of or known brain metastases, spinal cord compression, or carcinomatous meningitis

• Known HIV

• Serious acute or chronic illness

• Current treatment on another clinical trial

• Pregnant or breastfeeding

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Stomach Neoplasms

Intervention

Drug:
• Sunitinib
50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed

Locations

Country	Name	City	State
China	Pfizer Investigational Site	Beijing
China	Pfizer Investigational Site	Beijing
China	Pfizer Investigational Site	Guangzhou
China	Pfizer Investigational Site	Nanjing	Jiangsu
Hong Kong	Pfizer Investigational Site	Hong Kong
Hong Kong	Pfizer Investigational Site	Shatin
Italy	Pfizer Investigational Site	Ancona
Italy	Pfizer Investigational Site	Genova
Japan	Pfizer Investigational Site	Chuo-ku	Tokyo
Japan	Pfizer Investigational Site	Kashiwa	Chiba
Japan	Pfizer Investigational Site	Suntougun	Shizuoka
Korea, Republic of	Pfizer Investigational Site	Seoul
Korea, Republic of	Pfizer Investigational Site	Seoul
Korea, Republic of	Pfizer Investigational Site	Seoul
Korea, Republic of	Pfizer Investigational Site	Seoul
Portugal	Pfizer Investigational Site	Porto
Taiwan	Pfizer Investigational Site	Kwei-Shan	Taoyuan
Taiwan	Pfizer Investigational Site	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

China,  Hong Kong,  Italy,  Japan,  Korea, Republic of,  Portugal,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Overall Response	Number of patients with best overall response = complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study =4 weeks after initial documentation of response. CR = the disappearance of all target lesions. PR = a =30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.	From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter	No
Primary	Objective Response (Complete Response (CR) or Partial Response (PR))	Number of patients with Objective Response (OR): confirmed CR or confirmed PR according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a =30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.	From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter	No
Secondary	Clinical Benefit Response (CBR)-Complete Response (CR), Partial Response (PR) or Stable Disease (SD) With Duration = 24 Weeks	Number of patients with Clinical Benefit Response: confirmed CR, confirmed PR or stable disease (SD) for at least 24 weeks on study according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR = the disappearance of all target lesions. PR = a =30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progessive disease (PD) taking as a reference the smallest sum of the longest dimensions since the treatment started.	From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or clinical benefit response for at least 24 weeks on study	No
Secondary	Duration of Response (CR or PR)	Time from the first documentation of confirmed objective response (CR or PR) to the first documentation of disease progression or to death due to any cause. CR = the disappearance of all target lesions. PR = a =30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.	Day 28 of Cycle 1 and Day 28 of Cycles thereafter or death due to cancer	No
Secondary	Progression-Free Survival	Time from start of study treatment to first documentation of objective tumor progression, or to death due to any cause. PFS was calculated as (first event date minus the date of first dose plus 1) divided by 7.	From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or death	No
Secondary	Time to Tumor Progression (TTP)	Time from the start of study treatment to the first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose plus 1) divided by 7.	From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter	No
Secondary	Overall Survival	Time from the date of first dose of study medication to the date of death due to any cause. OS was calculated as (date of death minus the date of first dose date plus 1) divided by 7.	From start of study treatment until death	No

External Links

•   To obtain contact information for a study center near you, click here.